March 2022 - Volume 81 - 3

Editorial

1. Hydroxychloroquine and lupus flare: a good drug, but we need to do better  

Viewpoint

2. Time to reconsider what Global Burden of Disease studies really tell us about low back pain

Criteria

3. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

4. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

5. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

Rheumatoid arthritis

6. Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study

7. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

8. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

Psoriatic arthritis

9. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

10. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Systemic lupus erythematosus

11. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Autoimmunity

12. Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood

Behcet’s disease

13. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome

Treatment

14. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study

15. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy

16. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

Epidemiology

17. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis

18. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations

19. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?

Letters

20. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases

21. Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2

22. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines

23. Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA

24. When extended genetics rescues diagnosis: a patient with CANDLE-like phenotype and de novo mutation in the SAMD9L gene

25. Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behçet’s syndrome?

Electronic pages

26. Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?

27. Response to: ‘Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?’ by Liu et al

28. Questions on ‘Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population’ by Guo et al

29. Response to: ‘Questions on ‘Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population’ by Guo et al’ by Regueiro and Gonzalez

30. Reactive arthritis, a missing link: comment on the recent article from Sepriano et al

31. Response to: ‘Reactive arthritis, a missing link: comment on the recent article from Sepriano et al’ by Zeidler and Hudson

32. Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index

33. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study

34. Glucocorticoid withdrawal in lupus – to do or not to do?

35. Response to: ‘Glucocorticoid withdrawal in lupus: to do or not to do?’ by Acharya

36. Comments on the article: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial”

37. Response to: ‘Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"’ by Mousavi and Taherifard

38. Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies

39. Response to: ‘Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies’ by Yang et al

40. Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis

41. MRI and ultrasonography are useful tools for a non-invasive diagnosis of IgG4-related disease

42. Features of polymyalgia rheumatica–like syndrome after immune checkpoint inhibitor therapy

Issue Information